We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Organ-on-a-Chip Platform Helps Devise Strategy to Treat Severe COVID-19 Complications

By HospiMedica International staff writers
Posted on 30 Mar 2022
Print article
Image: A novel anti-inflammatory peptide could prevent cytokine storm in COVID-19 patients (Photo courtesy of University of Toronto)
Image: A novel anti-inflammatory peptide could prevent cytokine storm in COVID-19 patients (Photo courtesy of University of Toronto)

Cytokine storms are known to occur in some patients with COVID-19, as well as other illnesses. They happen when the body releases a large number of signaling proteins called cytokines in the blood. Too many cytokines push the immune system into overdrive and can lead to vascular complications, multi-organ failure and even death. One of the greatest challenges for clinicians during the COVID-19 pandemic has been to understand why some people infected by the SARS-CoV-2 virus experience cytokine storms, while others do not. Using their novel organ-on-a-chip platform, researchers have now identified a molecule with the potential to combat cytokine storms, one of the most severe complications of COVID-19 infections.

The research team at the University of Toronto (Ontario, Canada) leveraged their expertise in organ-on-a-chip technology to identify the molecule, a novel anti-inflammatory peptide called QHREDGS that does not act on the virus directly. Instead, it works to prevent cytokine storm, a potentially life-threatening immune reaction. The team comprises experts in growing functional cardiac tissue outside the human body. These lab-grown tissues allow researchers to model diseases and understand how genetic mutations in cardiac tissues can cause cardiac failures.

The research team had recently carried out a study using a specific model tissue platform known as integrated vasculature for assessing dynamic events (InVADE). Using the InVADE platform, they infected a microfabricated perfusable blood vessel-on-a-chip with SARS-CoV-2 to understand how the virus triggers inflammation and vascular dysfunction. They also screened five compounds with anti-inflammatory properties that had been previously tested by clinicians to see if any of them showed promise in preventing the cytokine storm.

QHREDGS is a peptide that had previously been found to improve cardiomyocyte metabolism and enhance endothelial cell survival. In the study, the researchers found that it enhanced vascular functions and repaired the harmful effects of SARS-CoV-2. For example, the function of a vascular structure known as the endothelial barrier was improved by 62% compared with endothelial cells without the peptide, and the secretion of some cytokine storm molecules had been decreased between 1,000 to 10,000 times.

The InVADE platform is being used for many other investigations by the researchers, including a study that explores why cancer is rarely found in the heart. The team is also using the vasculature-on-a-chip system to better understand the causes of myocarditis that have been seen in COVID-19 patients, as well as in some individuals who have been vaccinated against the disease. The team is currently collaborating with other clinicians and researchers to find unique biomolecular markers associated with myocarditis. The researchers hope this type of organ-on-a-chip system will enable researchers to predict and better respond to future public health events.

“During the pandemic, we repurposed our cardiac tissue platforms to understand how the SARS-CoV-2 virus can cause vascular dysfunction,” said Rick Lu, a PhD candidate. “Vascular dysfunction can allow SARS-CoV-2 to penetrate into a person’s organs, such as the heart, liver and intestine. By improving vascular function and reducing inflammation in the body, we hope to prevent the kind of organ failure that has been seen in COVID-19 patients.”

Related Links:
University of Toronto 

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Vibrating Mesh Nebulizer
Aerogen Solo

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.